STOCK TITAN

Klotho Neurosciences, Inc. - KLTO STOCK NEWS

Welcome to our dedicated page for Klotho Neurosciences news (Ticker: KLTO), a resource for investors and traders seeking the latest updates and insights on Klotho Neurosciences stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Klotho Neurosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Klotho Neurosciences's position in the market.

Rhea-AI Summary

Klotho Neurosciences (NASDAQ: KLTO) has appointed Dr. Merit Cudkowicz to its Scientific Advisory Board. Dr. Cudkowicz is the Chair of Neurology at Massachusetts General Hospital, Director of the Sean M. Healey & AMG Center for ALS, and Julieanne Dorn Professor of Neurology at Harvard Medical School. She is a member of the National Academy of Medicine and co-director of the Northeast ALS Consortium, overseeing 150+ clinical sites in the US and Canada.

The company, focused on developing cell and gene therapies for ALS, Alzheimer's, and Parkinson's disease, aims to leverage Dr. Cudkowicz's expertise in clinical trial design and execution. Their approach centers on a patent-protected product candidate expressing the Klotho gene transcribed protein called 's-KL' or 'secreted Klotho' for ALS treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
management
-
Rhea-AI Summary

Klotho Neurosciences (NASDAQ: KLTO) has appointed Riad El-Dada, former US President of Merck, to its Board of Directors. During his tenure at Merck, El-Dada managed over $12 billion in revenue across multiple therapeutic areas and served as Managing Director for Australia and New Zealand operations. His experience includes product development, commercialization, strategic partnerships, and policy engagement through the Healthcare Leadership Council. The appointment aims to strengthen the company's development of S-KL, a patent-protected Klotho gene therapy targeting ALS, Alzheimer's, and Parkinson's diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
management
-
Rhea-AI Summary

Klotho Neurosciences (NASDAQ: KLTO) announces the appointment of Dr. Makoto Kuro-o to its Scientific Advisory Board. Dr. Kuro-o is renowned for discovering the Klotho gene, known as the 'anti-aging gene,' during his research at the National Institute of Neuroscience in Tokyo. His research showed that mice lacking the Klotho gene aged faster, while those overexpressing it lived longer. The company is developing a patent-protected secreted form of Klotho (s-KL) for treating neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.57%
Tags
none
Rhea-AI Summary

Klotho Neurosciences (NASDAQ: KLTO) has appointed Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its new Chief Operating Officer (COO). This strategic move aims to strengthen the company's leadership team and accelerate the development of its therapeutic candidates. Moriarty brings extensive experience in the pharmaceutical industry, including leadership roles at multinational companies and entrepreneurial success.

Dr. Joseph Sinkule, Chairman, CEO, and Founder of Klotho Neurosciences, highlighted Moriarty's expertise in operational management, strategic execution, and corporate culture development. Moriarty expressed enthusiasm for joining KLTO, citing its robust portfolio and promising cell and gene therapy platform. The company's focus is on developing breakthrough treatments for neurodegenerative diseases like ALS, Alzheimer's, and Parkinson's, leveraging its exclusive worldwide license from the Autonomous University of Barcelona for treatments based on the secreted form of the Klotho gene (s-KL).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
management
-
Rhea-AI Summary

Klotho Neurosciences (NASDAQ: KLTO) has announced that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board. Dr. Langer, a renowned biotech leader and MIT professor, will contribute his expertise in neuroscience and therapeutics development. Klotho Neurosciences is developing novel therapies for neurodegenerative diseases, leveraging research on the Klotho protein, an anti-aging factor with neuroprotective potential.

The company's platform focuses on the secreted form of Klotho, s-KL, which is patented in several countries. Dr. Joseph Sinkule, Chairman and CEO of Klotho Neurosciences, expressed enthusiasm about Dr. Langer's vast experience in translational medicine and therapeutic innovation. Dr. Langer will provide guidance on the scientific and clinical development of the company's product candidates, supporting efforts to address major unmet medical needs in neurodegenerative disorders such as ALS, Alzheimer's, and Parkinson's disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.95%
Tags
management

FAQ

What is the current stock price of Klotho Neurosciences (KLTO)?

The current stock price of Klotho Neurosciences (KLTO) is $0.47 as of December 24, 2024.

What is the market cap of Klotho Neurosciences (KLTO)?

The market cap of Klotho Neurosciences (KLTO) is approximately 10.9M.

Klotho Neurosciences, Inc.

Nasdaq:KLTO

KLTO Rankings

KLTO Stock Data

10.93M
9.30M
56.28%
11.42%
0.67%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
NEW YORK